{"Clinical Trial ID": "NCT00191789", "Intervention": ["INTERVENTION 1:", "- Gemcitabine+Doxorubicin+Cisplatinum+surgery", "Gemcitabine: 1200 mg/m^2, day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, day 1 and day 8 every 21 days x 4 cycles (5-8).", "Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy."], "Eligibility": ["Incorporation criteria:", "Diagnosis of breast carcinoma", "No previous chemotherapy, with locally advanced disease two-dimensionally measurable", "- Adequate performance (Karnofsky Performance Status [KPS] greater than or equal to 70), bone marrow reserves, liver, heart and kidney function.", "- Exclusion criteria:", "Inflammatory breast cancer", "Pregnancy and lactation", "Serious concomitant disorders or infections", "A prior cancer in the last 5 years or a second primary malignancy."], "Results": ["Performance measures:", "Number of patients with complete pathological response (full pathological response rate)", "Complete pathological response: No invasive tumour cells identified from sections of the previous cancer site. Requires evidence to corroborate the previous presence of invasive cancer, which requires the detection of an abnormal fibroelastic breast stroma without normal lobular units and contains sparkling macrophages with a moderate number of mononuclear fibroblasts and inflammatory cells.", "Time: Assessment of tumour at base and during surgery after eight 21-day treatment cycles", "Results 1:", "- Arm/group title: Gemcitabine+Doxorubicin+Cisplatinum+surgery", "Description of the arm/group: Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV day 1 and day 8 every 21 days x 4 cycles (5-8).", "Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy.", "Total number of participants analysed: 65", "Type of measurement: Number", "Unit of measurement: participants 13"], "Adverse Events": ["Undesirable Events 1:", "Total: 17/65 (26.15 per cent)", "- Febrile neutropenia 3/65 (4.62 %)", "Neutropenia 2/65 (3.08%)", "Pancytopenia 1/65 (1.54%)", "Thrombocytopenia 1/65 (1.54%)", "Cardiac arrest 2/65 (3.08%)", "Myocardial infarction 1/65 (1.54%)", "Diarrhoea 5/65 (7.69%)", "Stomatitis 1/65 (1.54%)", "Vomiting 2/65 (3.08%)", "Fatigue 1/65 (1.54%)", "Jaundice index 1/65 (1.54%)", "- Neutropenic infection 2/65 (3.08%)"]}